Chest computed tomography versus serum galactomannan enzyme immunoassay for the diagnosis of probable invasive aspergillosis: to be decided.

Clinical outcomes in patients with invasive aspergillosis have significantly improved [1, 2]. This may, in part, be related to earlier diagnosis, leading to earlier institution of treatment and better tolerated, effective, and safe treatment options [2, 3]. The study of diagnostic and therapeutic modalities for invasive aspergillosis has been greatly facilitated by the introduction of definitions for invasive fungal infections established by the European Organization for Research and Treatment of Cancer and the Mycosis Study Group (EORTC-MSG) in 2002, which have recently been updated and published in this journal [4, 5]. On the basis of the EORTC-MSG definitions, an invasive fungal infection is considered to be proven (usually requiring tissue biopsy), probable, or possible. The presence of a microbiologic diagnosis in addition to host, clinical, and radiographic factors differentiates a probable from a possible invasive fungal infection [4, 5]. These def-